XMAD
FAE
Market cap1.65bUSD
Sep 17, Last price
4.62EUR
1D
0.87%
1Q
1.32%
Jan 2017
37.50%
Name
Faes Farma SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Related entities
Subsidiaries (3)
COLPHARMA S.R.L.
FAES FARMA MEXICO SA DE CV
LAZLO INTERNATIONAL SA
Key people
Mariano Ucar Angulo
Chairman of the Board, Other External Director · since 2024
Valentin Ruiz Unamunzaga
Chief Financial Officer · since 2024
Carlos Gutierrez Aguero
Chief People Officer · since 2024
Jaime Lopez
Global Head - IT
Alberto Fernandez Fernandez
Chief Marketing and Portfolio Strategy Officer · since 2024
Isabel Najera
Chief Scientific and Medical Officer
Mariana Soroa Zubiria
Chief GRC & Internal Audit Officer · since 2024
Eduardo Recoder De La Cuadra
Chief Executive Officer, Executive Director · since 2024
Maria Marin
Head - Investor Relations & External Comms
Xavier Arnaud
Chief Business Development Officer · since 2024
Helder Cassis
Country Manager, Portugal · since 2024
Jose Luis Diaz Capote
Chief International Business Officer · since 2024
German Fernandez-Cano Diaz
Chief Farm Faes Business Officer · since 2024
Esther Mosquera
Country Manager, Spain
Tom Van Ommen
Head - Corporate Controlling
Juan Veiga
Head - Transformation Office
Non-Member Secretary of the Board · since 2022
Carmen Basagoiti Pastor
Proprietary Director · since 2011
Gonzalo Fernandez de Valderrama Iribarnegaray
Proprietary Director · since 2022
Inigo Zavala Ortiz de la Torre
Proprietary Director · since 1994
Headquarters & legal address
AVENIDA AUTONOMIA, 10-
Leioa 48940
ES
Leioa 48940
ES
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||